• Celtic Pharmaceutical Holdings LP, of New York, said it completed a Phase I/II study of Xerecept (corticorelin acetate) in pediatric patients who are dependent on the steroid Decadron (dexamethasone) to treat peritumoral brain edema associated with cerebral tumors. Initial indications from the 15-patient study indicated that Xerecept can reduce or eliminate the need for Decadron use and provide significant quality of life improvements.
